Literature DB >> 3708605

Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine.

J F Demonet, M Rostin, J M Dueymes, A Ioualalen, J L Montastruc, A Rascol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3708605     DOI： 10.1097/00002826-198604000-00012

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  4 in total

1.  Retroperitoneal fibrosis in a patient with macroprolactinoma treated with bromocriptine.

Authors:  A Herzog; H Minne; R Ziegler
Journal:  BMJ       Date:  1989-05-13

2.  Pleuropulmonary and retroperitoneal fibrosis associated with bromocriptine treatment.

Authors:  C D Ward; J Thompson; M D Humby
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-12       Impact factor: 10.154

3.  Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.

Authors:  M M Pinter; O Pogarell; W H Oertel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-04       Impact factor: 10.154

4.  Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease.

Authors:  R J Uitti; J E Ahlskog
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.